KB Home Coverage Initiated at Sterne Agee (KBH)

Investment analysts at Sterne Agee began coverage on shares of KB Home (NYSE: KBH) in a note issued to investors on Wednesday. The firm set a “neutral” rating on the stock.

KB Home traded up 0.80% on Wednesday, hitting $20.28. KB Home has a 1-year low of $6.46 and a 1-year high of $20.76. The stock’s 50-day moving average is currently $18.84. The company’s market cap is $1.566 billion.

KB Home last posted its quarterly earnings results on Thursday, December 20th. The company reported $0.10 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.06 by $0.04. The company had revenue of $578.20 million for the quarter, compared to the consensus estimate of $567.06 million. During the same quarter last year, the company posted $0.18 earnings per share. KB Home’s revenue was up 20.5% compared to the same quarter last year. Analysts expect that KB Home will post $0.13 EPS for the current fiscal year.

A number of other firms have also recently commented on KBH. Analysts at RBC Capital raised their price target on shares of KB Home from $19.00 to $22.00 in a research note to investors on Friday, March 8th. They now have an “outperform” rating on the stock. Separately, analysts at Bank of America initiated coverage on shares of KB Home in a research note to investors on Wednesday, February 27th. They set a “buy” rating on the stock. Finally, analysts at Bank of America initiated coverage on shares of KB Home in a research note to investors on Wednesday, February 27th. They set a “buy” rating and a $24.00 price target on the stock.

Five research analysts have rated the stock with a buy rating, eleven have given a hold rating, two have given an underweight rating, and three have issued a sell rating to the stock. The stock has an average rating of “hold” and a consensus price target of $18.17.

KB Home is a homebuilding company. The Company constructs and sells homes through its operating divisions under the name KB Home.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.

Latest News

Supreme Court Allows Regulators to Challenge Generic Drug Agreements
Supreme Court Allows Regulators to Challenge Generic Drug Agreements
Car Sales in Europe Hit Record Lows
Car Sales in Europe Hit Record Lows
Woman once on Death Row to Go Free
Woman once on Death Row to Go Free
Bidding for Back Bay Parking Spaces Reaches $560,000
Bidding for Back Bay Parking Spaces Reaches $560,000
Vermont Grappling with Nation’s Second Highest Rate of Lyme disease
Vermont Grappling with Nation’s Second Highest Rate of Lyme disease
Concerns about Origins of Genetically Modified Wheat Affect US White Wheat
Concerns about Origins of Genetically Modified Wheat Affect US White Wheat


Leave a Reply

 
© 2010-2013 Zolmax.com, LLC.
Subscribe Subscribe